Amit Awasthi
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
Amit Awasthi is a professor at the Translational Health Science and Technology Institute, India.[1].
He is an immunologist, and his research interests lie in understanding the biology of helper T cells. Prof. Awasthi specializes in immuno-biology, autoimmunity, and cancer immunotherapy. He is best known for his work in the differentiation of subsets of immune cells called T helper 17 cells, Type 1 regulatory T cell, and Th 9 cell. During the COVID-19 pandemic, Dr. Awasthi played a prominent role in leading the pre-clinical vaccine efficacy studies and cell mediated immunogenicity clinical studies of several COVID-19 vaccine candidates.
Education[edit]
Amit Awasthi completed his bachelor's in biology and master's degree in biotechnology from Jiwaji University, Gwalior, and further pursued his Ph.D. in biotechnology/immunology from the National Centre for Cell Science, Pune. He completed his post-doctoral training at Brigham and Women's Hospital and Harvard Medical School. Later he joined as a Junior faculty instructor at the Harvard Medical School and continued there as visiting scientist until August 2016 [2]. In 2012, he joined THSTI, Faridabad, India, as an assistant professor.
Honours And Awards[edit]
- The Innovative Young Biotechnologist Award from Department of Biotechnology, Government of India in 2011 [3].
- The Ramalingaswami Fellowship from the Department of Biotechnology, India in 2011 [4].
- Young scientist platinum jubilee award in biological sciences from National Academy of Sciences, India in 2012 [5]
- G.P. Talwar Mid-Career Scientist Award of Indian Immunology Society India in 2017 [6].
- National Bioscience Award for Career Development, Department of Biotechnology, Govt. of India [7].
- CSIR-Central Drug Research Institute Award (2020) for the excellence in Drug Research under Life Sciences category by CSIR-Central Drug Research Institute, Lucknow, India. [8]
Memberships & Editorial Board[edit]
He is serving as the secretary at the Indian Immunology Society (IIS) [9] and a member of the American Association of Immunologists.
He is also a member of editorial boards of esteemed journals, namely, Frontiers in Immunology [10], Journal of Gastroenterology Forecast [11], Immunology [12], and Frontiers in pharmacology [13].
Contribution During COVID-19 Pandemic[edit]
Awasthi was a part of the group that evaluated the effectiveness of the COVISHIELD vaccine (ChAdOx1-nCoV19) against the delta variant of SARS-CoV-2 on behalf of the Department of Biotechnology, India Consortium for COVID-19 research [14]. Also, the Immunogenicity and Safety of Covaxin (BBV152) were evaluated in a study carried out in collaboration with Bharat Biotech International Ltd. [15]. He was also one of the supervisors of the team that designed a highly potent monoclonal antibody, P4A2, with the capability to neutralize all the SARS-CoV-2 variants of concern [16].
Awasthi and his team at the Immunology Core Lab, THSTI, performed the efficacy testing of the Sputnik V vaccine. The study was a part of clinical trials for Phase II and Phase III of the vaccine in India [17]. The data contributed significantly to the emergency use authorization for the Sputnik V vaccine from the Drug Controller General of India (DCGI). Awasthi's lab also carried out pre-clinical studies of the ZyCoV-D vaccine manufactured by Zydus Cadila and Biological E's Corbevax vaccine. Preclinical trials were carried out in hamster model for SARS-CoV-2 infection at THSTI. ZyCoV-D is a DNA-plasmid-based vaccine that carries the gene encoding the spike proteins of SARS-CoV-2. At THSTI, challenge studies were carried out with live SARS-CoV-2 virus (Wuhan strain) in immunized hamsters. Following the successful pre-clinical trial of the ZyCoV-D at THSTI and its subsequent success in clinical trial studies, the ZyCoV-D vaccine has been given emergency approval by DCGI. [18][19].
Corbevax is India's first indigenously developed RBD-protein subunit vaccine that Hyderabad-based Biological E Limited has manufactured. Under the leadership of Prof. Awasthi, Immunology Core Lab performed the pre-clinical studies of Corbevax in hamsters and tested the cell-mediated immunity during the phase II and III clinical trials of Corbevax. These studies at THSTI contributed to Corbevax getting approval for Phase III trials by the Government of India [20][21].
News[edit]
Dr Awasthi's research work has caught the attention of the media from time to time. His work on the therapeutic effect of potassium on inflammatory bowel disease and other autoimmune diseases was covered by The Indian Express in 2016 and the Free Press Journal in 2019 [22][23] His commentary on the study carried out to evaluate the effectiveness of Covaxin[24] was widely covered by significant newspapers, namely The Wire and The Hindu [25][26] The Scientist in 2021 covered the study reported by Prof. Awasthi and his team about the role of a high salt diet on tumor progression.[27]
Refernces[edit]
- ↑ https://thsti.res.in/newthsti/en/faculty-profile/Amit-Awasthi
- ↑ "People – Discover Brigham".
- ↑ Malik, Sakshi; Sadhu, Srikanth; Elesela, Srikanth; Pandey, Ramendra Pati; Chawla, Amanpreet Singh; Sharma, Deepak; Panda, Lipsa; Rathore, Deepak; Ghosh, Balram; Ahuja, Vineet; Awasthi, Amit (October 9, 2017). "Transcription factor Foxo1 is essential for IL-9 induction in T helper cells". Nature Communications. 8 (1): 815. Bibcode:2017NatCo...8..815M. doi:10.1038/s41467-017-00674-6. PMC 5634439. PMID 28993609.
- ↑ "List of Fellows". April 14, 2012.
- ↑ "The National Academy of Sciences, India - NASI-Young Scientist Platinum Jubilee Awards 2012".
- ↑ http://indianimmunology.org/news/pdf/iisawards.pdf[bare URL PDF]
- ↑ https://dbtindia.gov.in/sites/default/files/ResultS.Ramachandran-NBACD-2020-21_0.pdf[bare URL PDF]
- ↑ https://cdri.res.in/pdf/award/CDRI_Awards2022.pdf[bare URL PDF]
- ↑ "IIS|Society".
- ↑ "Frontiers - Search". www.frontiersin.org.
- ↑ "Editors | Journal of Gastroenterology Forecast | Clinical and Medical Category".
- ↑ https://onlinelibrary.wiley.com/page/journal/13652567/homepage/editorialboard.html
- ↑ "Frontiers - Search". www.frontiersin.org.
- ↑ Thiruvengadam, R.; et al. (2022). "Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses". The Lancet. Infectious Diseases. 22 (4): 473–482. doi:10.1016/S1473-3099(21)00680-0. PMC 8616567 Check
|pmc=value (help). PMID 34838183 Check|pmid=value (help). - ↑ Ganneru, Brunda; Jogdand, Harsh; Dharam, Vijaya Kumar; Molugu, Narasimha Reddy; Prasad, Sai D.; Vellimudu, Srinivas; Ella, Krishna M.; Ravikrishnan, Rajaram; Awasthi, Amit; Jose, Jomy; Rao, Panduranga; Kumar, Deepak; Ella, Raches; Abraham, Priya; Yadav, Pragya; Sapkal, Gajanan N.; Shete, Anita; Desphande, Gururaj Rao; Mohandas, Sreelekshmy; Basu, Atanu; Gupta, Nivedita; Vadrevu, Krishna Mohan (September 12, 2020). "Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152": 2020.09.09.285445. doi:10.1101/2020.09.09.285445 – via bioRxiv. Unknown parameter
|s2cid=ignored (help) - ↑ "A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns". www.researchsquare.com. March 14, 2022.
- ↑ "Russia's Sputnik V vaccine found safe in mid-stage trial in India: Dr Reddy's". mint. January 11, 2021.
- ↑ https://thsti.res.in/newthsti/public/upload/annual_reports/1640263750pdf.pdf[bare URL PDF]
- ↑ "Thsti - Translational Health Science and Technology Institute". thsti.res.in.
- ↑ Das, Sohini (February 21, 2022). "Corbevax becomes third Covid vaccine to be approved for children in India" – via Business Standard.
- ↑ Thuluva, Subhash; Paradkar, Vikram; Turaga, Kishore; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan; Suneetha, P. V.; Kyasani, Mahesh; Manoharan, Senthil Kumar; Adabala, Srikanth; Javvadi, Aditya Sri; Medigeshi, Guruprasad; Singh, Janmejay; Shaman, Heena; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Singh, Chandramani; Rao, A. Venkateshwar; Basu, Indranil; Kumar, Khobragade Akash Ashok; Pandey, Anil Kumar (March 22, 2022). "Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial": 2022.03.20.22271891. doi:10.1101/2022.03.20.22271891 – via medRxiv. Unknown parameter
|s2cid=ignored (help) - ↑ "From the lab: For inflamed bowels, solution could lie in potassium intake". December 12, 2016.
- ↑ "Salt is more harmful than doctors thought". Free Press Journal.
- ↑ Thiruvengadam, R.; Binayke, A.; Awasthi, A. (2022). "SARS-CoV-2 delta variant: A persistent threat to the effectiveness of vaccines". The Lancet. Infectious Diseases. 22 (3): 301–302. doi:10.1016/S1473-3099(21)00697-6. PMC 8610239 Check
|pmc=value (help). PMID 34826382 Check|pmid=value (help). - ↑ Kaur, Banjot. "Covaxin Is 50% Effective, New Study Says. What Does That Mean Exactly? – The Wire Science".
- ↑ "Experts allay Covaxin concerns, say 50% effectiveness against Delta-driven COVID-19 surge not bad". The Hindu. November 25, 2021 – via www.thehindu.com.
- ↑ "Salty Diet Helps Gut Bugs Fight Cancer in Mice: Study". The Scientist Magazine®.
External links[edit]
- Amit Awasthi publications indexed by Google Scholar
This article "Amit Awasthi" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Amit Awasthi. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
